The IAEA has recently launched SAFRON for Radionuclide Therapy, an incident learning system to help medical facilities improve safety of patients and staff. The objective of this new learning system ...

In terms of patient selection, workgroup members agreed that PSMA PET should be performed within three months of treatment or since progression on the last therapy to ensure that the current disease ...

Researchers in Japan are developing world-leading expertise in making and using the alpha particle emitter, astatine-211 (211 At), which has potential for use as a strong radionuclide therapy for ...

After the Fukushima nuclear power plant accident, managing environmental radionuclide contamination efficiently has become incredibly important. In light of this, a team of scientists have provided ...

If you would like to learn more about the IAEA’s work, sign up for our weekly updates containing our most important news, multimedia and more. Nuclear medicine plays a very important role in the ...

Transaxial slices of baseline positron emission tomography (PET) and fused PET/magnetic resonance imaging (MRI; left) demonstrate a somatostatin receptor-expressing meningioma in the left cavernous ...

Prostate cancer is the most common cancer in men and at later stages of the disease many patients develop painful bone metastases. One promising modality for management of skeletal metastases is ...

Reston, VA (September 28, 2021)—A promising radionuclide treatment may offer new therapeutic options for breast cancer patients, according to research published in The Journal of Nuclear Medicine. The ...

γ-emitting isotopes are selected for diagnosis because the radiation they produce can be detected by specific instruments such as positron emission tomography (PET) or single-photon emission computed ...

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the first clinical site for the Phase 1/2 LuMIERE study of FAP-2286, its novel peptide-targeted radionuclide ...